The effect of commencing combination antiretroviral therapy soon after human immunodeficiency virus type 1 infection on viral replication and antiviral immune responses - PubMed (original) (raw)
Clinical Trial
. 1999 Mar;179(3):527-37.
doi: 10.1086/314628.
M Vesanen, K Tenner-Racz, Y Cao, J M Binley, A Talal, A Hurley, X Jin, M R Chaudhry, M Yaman, S Frankel, M Heath-Chiozzi, J M Leonard, J P Moore, P Racz, D F Nixon, D D Ho
Affiliations
- PMID: 9952358
- DOI: 10.1086/314628
Clinical Trial
The effect of commencing combination antiretroviral therapy soon after human immunodeficiency virus type 1 infection on viral replication and antiviral immune responses
M Markowitz et al. J Infect Dis. 1999 Mar.
Erratum in
- J Infect Dis 1999 May;179(5):1315. J X [corrected to Jin X]
Abstract
Twelve subjects were treated with zidovudine, lamivudine, and ritonavir within 90 days of onset of symptoms of acute infection to determine whether human immunodeficiency virus type 1 (HIV-1) infection could be eradicated from an infected host. In adherent subjects, with or without modifications due to intolerance, viral replication was suppressed during the 24-month treatment period. Durable suppression reduced levels of HIV-1-specific antibodies and cytotoxic T lymphocyte responses in selected subjects. Proviral DNA in mononuclear cells uniformly persisted. The persistence of HIV-1 RNA expression in lymphoid tissues and peripheral blood mononuclear cells suggests that elimination of this residual pool of virus should be achieved before considering adjustments in antiretroviral therapeutic regimens. In addition, given the reduction in levels of virus-specific immune responses, it would seem prudent to consider enhancing these responses using vaccine strategies prior to the withdrawal of antiviral therapy.
Similar articles
- Prolonged suppression of human immunodeficiency virus type 1 (HIV-1) viremia in persons with advanced disease results in enhancement of CD4 T cell reactivity to microbial antigens but not to HIV-1 antigens.
Rinaldo CR Jr, Liebmann JM, Huang XL, Fan Z, Al-Shboul Q, McMahon DK, Day RD, Riddler SA, Mellors JW. Rinaldo CR Jr, et al. J Infect Dis. 1999 Feb;179(2):329-36. doi: 10.1086/314599. J Infect Dis. 1999. PMID: 9878015 Clinical Trial. - Immune reconstitution after 2 years of successful potent antiretroviral therapy in previously untreated human immunodeficiency virus type 1-infected adults.
Notermans DW, Pakker NG, Hamann D, Foudraine NA, Kauffmann RH, Meenhorst PL, Goudsmit J, Roos MT, Schellekens PT, Miedema F, Danner SA. Notermans DW, et al. J Infect Dis. 1999 Oct;180(4):1050-6. doi: 10.1086/315013. J Infect Dis. 1999. PMID: 10479130 Clinical Trial. - Potent antiretroviral therapy of primary human immunodeficiency virus type 1 (HIV-1) infection: partial normalization of T lymphocyte subsets and limited reduction of HIV-1 DNA despite clearance of plasma viremia.
Zaunders JJ, Cunningham PH, Kelleher AD, Kaufmann GR, Jaramillo AB, Wright R, Smith D, Grey P, Vizzard J, Carr A, Cooper DA. Zaunders JJ, et al. J Infect Dis. 1999 Aug;180(2):320-9. doi: 10.1086/314880. J Infect Dis. 1999. PMID: 10395845 Clinical Trial. - Molecular biological assessment methods and understanding the course of the HIV infection.
Katzenstein TL. Katzenstein TL. APMIS Suppl. 2003;(114):1-37. APMIS Suppl. 2003. PMID: 14626050 Review. - Antiretroviral chemotherapy of human immunodeficiency virus infections other than with azidothymidine.
Sachs MK. Sachs MK. Arch Intern Med. 1992 Mar;152(3):485-501. Arch Intern Med. 1992. PMID: 1546911 Review.
Cited by
- Influence of Combination Antiretroviral Therapy on HIV-1 Serological Responses and Their Implications: A Systematic Review and Meta-Analysis.
Liang Y, Lin H, Dzakah EE, Tang S. Liang Y, et al. Front Immunol. 2022 Mar 30;13:844023. doi: 10.3389/fimmu.2022.844023. eCollection 2022. Front Immunol. 2022. PMID: 35432309 Free PMC article. - Irreversible phenotypic perturbation and functional impairment of B cells during HIV-1 infection.
Yan J, Zhang S, Sun J, Xu J, Zhang X. Yan J, et al. Front Med. 2017 Dec;11(4):536-547. doi: 10.1007/s11684-017-0592-x. Epub 2017 Nov 27. Front Med. 2017. PMID: 29181691 - A public health approach to addressing and preventing misdiagnosis in the scale-up of HIV rapid testing programmes.
Johnson CC, Dalal S, Baggaley R, Taegtmeyer M. Johnson CC, et al. J Int AIDS Soc. 2017 Aug 29;20(Suppl 6):22190. doi: 10.7448/IAS.20.7.22190. J Int AIDS Soc. 2017. PMID: 28872270 Free PMC article. No abstract available. - Eulogy for the clinical research center.
Nathan DG, Nathan DM. Nathan DG, et al. J Clin Invest. 2016 Jul 1;126(7):2388-91. doi: 10.1172/JCI88381. Epub 2016 Jun 6. J Clin Invest. 2016. PMID: 27270173 Free PMC article. - A Randomized Trial of Time-Limited Antiretroviral Therapy in Acute/Early HIV Infection.
Margolick JB, Apuzzo L, Singer J, Wong H, Lee T, Gallant JE, El-Helou P, Loutfy MR, Rachlis A, Fraser C, Kasper K, Tremblay C, Tossonian H, Conway B. Margolick JB, et al. PLoS One. 2015 Nov 24;10(11):e0143259. doi: 10.1371/journal.pone.0143259. eCollection 2015. PLoS One. 2015. PMID: 26600459 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical